Compare
Nexentis Technologies Inc. vs Incannex Healthcare Inc. vs Evofem Biosciences, Inc. vs Emmaus Life Sciences, Inc.
| Latest fiscal year | Nexentis Technologies Inc. NXTS | Incannex Healthcare Inc. IXHL | Evofem Biosciences, Inc. EVFM | Emmaus Life Sciences, Inc. EMMA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $86.0K | $20.18M | $12.45M |
| Revenue growth (YoY) | n/a | +616.7% | +4.2% | -25.2% |
| Gross margin | n/a | n/a | 77.1% (computed) | 93.1% |
| Operating margin | n/a | n/m | 16.7% | 1.9% |
| Net margin | n/a | n/m | 1.9% | -60.2% |
| Net income | -$4.00M | -$46.88M | $391.0K | -$7.49M |
| EPS (Diluted) | -$8.61 | -$1.35 | $0.00 | -$0.12 |
| Operating cash flow | -$3.81M | -$12.51M | -$1.99M | -$11.0K |
| Free cash flow | -$3.82M | -$12.52M | -$2.00M | -$12.0K |
| Cash & equivalents | $3.83M | $15.04M | $578.0K | $2.13M |
| Total assets | $20.41M | $20.45M | $20.27M | $21.44M |
| Total liabilities | $4.67M | $7.06M | $89.71M | $85.04M |
| Shareholders' equity | $16.01M | $13.39M | -$74.34M | -$63.61M |
| Return on year-end equity | -25.0% | -350.2% | n/a | n/a |
| Shares outstanding | 2.77M | 194.38M | 126.69M | 70.19M |
Revenue, most recent five fiscal years
| Fiscal year | Nexentis Technologies Inc. | Incannex Healthcare Inc. | Evofem Biosciences, Inc. | Emmaus Life Sciences, Inc. |
|---|---|---|---|---|
| Latest | $210.0K Ended 2024-12-31 | $86.0K Ended 2025-06-30 | $20.18M Ended 2025-12-31 | $12.45M Ended 2025-12-31 |
| 1 year earlier | $263.0K Ended 2023-12-31 | $12.0K Ended 2024-06-30 | $19.36M Ended 2024-12-31 | $16.65M Ended 2024-12-31 |
| 2 years earlier | $394.0K Ended 2022-12-31 | n/a | $18.22M Ended 2023-12-31 | $29.60M Ended 2023-12-31 |
| 3 years earlier | $438.1K Ended 2021-12-31 | n/a | $16.84M Ended 2022-12-31 | $18.39M Ended 2022-12-31 |
| 4 years earlier | $232.3K Ended 2020-12-31 | n/a | $8.24M Ended 2021-12-31 | $20.61M Ended 2021-12-31 |